Patents by Inventor Yingxia Wen
Yingxia Wen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240300994Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: ApplicationFiled: May 15, 2024Publication date: September 12, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
-
Patent number: 12018044Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: GrantFiled: January 25, 2021Date of Patent: June 25, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berlanda Scorza, Yingxia Wen, Andrew Geall, Frederick Porter
-
Publication number: 20240024455Abstract: The present disclosure relates to multicistronic RNA vaccines and uses thereof. The present disclosure also relates to multicistronic conventional mRNA vaccines and uses thereof.Type: ApplicationFiled: December 2, 2021Publication date: January 25, 2024Inventors: Pirada ALLEN, Ivna DE SOUZA, Yingxia WEN, Sukhmani BEDI, Cheng CHANG
-
Publication number: 20240024460Abstract: The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self-replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a Spike (S) protein or a nucleocapsid (N) protein.Type: ApplicationFiled: December 2, 2021Publication date: January 25, 2024Inventors: Pirada ALLEN, Ivna DE SOUZA, Yingxia WEN, Cheng CHANG, CHANGKEUN Lee
-
Publication number: 20220106364Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Inventors: Andrea CARFI, Yingxia WEN
-
Patent number: 11249088Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.Type: GrantFiled: July 29, 2019Date of Patent: February 15, 2022Assignee: Seqirus UK LimitedInventors: Yingxia Wen, Ethan Settembre, Zihao Wang
-
Patent number: 11155572Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: GrantFiled: March 13, 2014Date of Patent: October 26, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berlanda Scorza, Yingxia Wen, Andrew Geall, Frederick Porter
-
Publication number: 20210214388Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: ApplicationFiled: January 25, 2021Publication date: July 15, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
-
Publication number: 20200200764Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.Type: ApplicationFiled: July 29, 2019Publication date: June 25, 2020Inventors: Yingxia WEN, Ethan SETTEMBRE, Zihao WANG
-
Patent number: 10414802Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.Type: GrantFiled: October 29, 2015Date of Patent: September 17, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea Carfi, Claudio Ciferri, Irmgard Hofmann, Holger Laux, Anders Lilja, Yingxia Wen
-
Patent number: 10416171Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.Type: GrantFiled: July 7, 2016Date of Patent: September 17, 2019Assignee: Seqirus UK LimitedInventors: Yingxia Wen, Ethan Settembre, Zihao Wang
-
Publication number: 20190211064Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.Type: ApplicationFiled: March 25, 2019Publication date: July 11, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea CARFI, Yingxia WEN
-
Patent number: 10287322Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.Type: GrantFiled: May 16, 2017Date of Patent: May 14, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea Carfi, Yingxia Wen
-
Publication number: 20180196061Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.Type: ApplicationFiled: July 7, 2016Publication date: July 12, 2018Inventors: Yingxia WEN, Ethan SETTEMBRE, Zihao WANG
-
Publication number: 20170362278Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.Type: ApplicationFiled: October 29, 2015Publication date: December 21, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea CARFI, Claudio CIFERRI, Irmgard HOFMANN, Holger LAUX, Anders LILJA, Yingxia WEN
-
Publication number: 20170320916Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.Type: ApplicationFiled: May 16, 2017Publication date: November 9, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea CARFI, Yingxia Wen
-
Patent number: 9683022Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.Type: GrantFiled: June 29, 2013Date of Patent: June 20, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea Carfi, Yingxia Wen
-
Publication number: 20160159864Abstract: This disclosure provides an isolated human cytomegalovirus (HCMV) membrane protein complex, wherein said complex comprises gH, gL and at least one more HCMV glycoprotein. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. The disclosure also provides processes for expressing and purifying said complexes, and subsequent uses of said complexes in immunogenic compositions and vaccines.Type: ApplicationFiled: June 29, 2013Publication date: June 9, 2016Inventors: Andrea Carfi, Yingxia Wen
-
Publication number: 20160024139Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.Type: ApplicationFiled: March 13, 2014Publication date: January 28, 2016Inventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
-
Publication number: 20120237545Abstract: A combination of ultrafiltration and HPLC is used to analyze influenza virus. This combination is able to quantify hemagglutinin (HA) and correlates well with single radial immunodiffusion (SRID) results, but can be performed without the delay of waiting for immunochemical SRID reagents.Type: ApplicationFiled: May 28, 2010Publication date: September 20, 2012Applicant: NORVARTIS AGInventors: Philip Dormitzer, Yingxia Wen, Paola Rinella, Gene Palmer